VIVO insider filings
VivoPower PLC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen VIVO transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 287,000 shares, $553,910 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 287,000 shares @ $1.93 ($553,910) by Chin Kevin, filed 2026-11-18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Chin Kevin — Chairman & CEO, Director, 10% owner | 1 | 1 leg · 287,000 sh · $553,910 | — | — |
Recent insider filings — VivoPower PLC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Chin Kevin — Chairman & CEO, Director, 10% owner | Purchase (P): 287,000 @ $1.93 | EDGAR |
| 2023-01-31 | 4 | Smith Julie Diana — Sr VP, Controller, PAO | Grant/award (A): 2,648 · Disposition to issuer (D): 32,708 · Disposition to issuer (D): 25,600 · Disposition to issuer (D): 2,000 (derivative) @ $27.03 | EDGAR |
| 2023-01-31 | 4 | Serafini-Lamanna Tony — Executive VP-Diagnostics | Grant/award (A): 7,945 · Disposition to issuer (D): 43,338 · Disposition to issuer (D): 10,000 (derivative) @ $19.40 · Disposition to issuer (D): 4,000 (derivative) @ $27.03 · Disposition to issuer (D): 12,107 (derivative) @ $15.52 · Disposition to issuer (D): 11,669 (derivative) @ $15.12 | EDGAR |
| 2023-01-31 | 4 | Kitzmiller Andrew S. — Executive Vice President & CFO | Grant/award (A): 7,945 · Disposition to issuer (D): 19,473 · Disposition to issuer (D): 5,000 (derivative) @ $9.26 | EDGAR |
| 2023-01-31 | 4 | Kenny John P. — Chief Executive Officer, Director, 10% owner | Grant/award (A): 47,060 · Disposition to issuer (D): 267,651 · Disposition to issuer (D): 66,039 (derivative) @ $23.90 · Disposition to issuer (D): 83,535 (derivative) @ $15.52 · Disposition to issuer (D): 82,940 (derivative) @ $15.12 | EDGAR |
| 2023-01-31 | 4 | Rice John McCune Jr. — Director | Disposition to issuer (D): 27,449 · Disposition to issuer (D): 12,000 (derivative) @ $17.80 · Disposition to issuer (D): 8,740 (derivative) @ $17.03 · Disposition to issuer (D): 5,796 (derivative) @ $12.64 · Disposition to issuer (D): 5,656 (derivative) @ $13.25 | EDGAR |
| 2023-01-31 | 4 | Williams Felicia — Director | Disposition to issuer (D): 10,274 · Disposition to issuer (D): 12,000 (derivative) @ $18.85 · Disposition to issuer (D): 8,740 (derivative) @ $17.03 · Disposition to issuer (D): 17,205 (derivative) @ $23.54 · Disposition to issuer (D): 5,796 (derivative) @ $12.64 · Disposition to issuer (D): 5,656 (derivative) @ $13.25 | EDGAR |
| 2023-01-31 | 4 | Sazdanoff Catherine — Director | Disposition to issuer (D): 16,424 · Disposition to issuer (D): 8,500 (derivative) @ $15.82 · Disposition to issuer (D): 8,500 (derivative) @ $15.36 · Disposition to issuer (D): 12,000 (derivative) @ $21.20 · Disposition to issuer (D): 12,000 (derivative) @ $17.80 · Disposition to issuer (D): 8,740 (derivative) @ $17.03 · +3 more | EDGAR |
| 2023-01-31 | 4 | McIlwraith John — Director | Disposition to issuer (D): 21,724 · Disposition to issuer (D): 8,500 (derivative) @ $15.82 · Disposition to issuer (D): 8,500 (derivative) @ $15.36 · Disposition to issuer (D): 10,000 (derivative) @ $21.20 · Disposition to issuer (D): 12,000 (derivative) @ $17.80 · Disposition to issuer (D): 8,740 (derivative) @ $17.03 · +3 more | EDGAR |
| 2023-01-31 | 4 | Ellingwood Dwight E — Director | Disposition to issuer (D): 17,290 · Disposition to issuer (D): 8,500 (derivative) @ $13.20 · Disposition to issuer (D): 5,500 (derivative) @ $16.66 · Disposition to issuer (D): 8,500 (derivative) @ $15.36 · Disposition to issuer (D): 11,000 (derivative) @ $21.20 · Disposition to issuer (D): 12,000 (derivative) @ $17.80 · +4 more | EDGAR |
| 2023-01-31 | 4 | Anderson James M. — Director | Disposition to issuer (D): 28,224 · Disposition to issuer (D): 5,000 · Disposition to issuer (D): 8,500 (derivative) @ $8.17 · Disposition to issuer (D): 8,500 (derivative) @ $16.66 · Disposition to issuer (D): 8,500 (derivative) @ $15.36 · Disposition to issuer (D): 12,000 (derivative) @ $21.20 · +5 more | EDGAR |
| 2023-01-31 | 4 | Bihl Anthony P III — Director | Disposition to issuer (D): 15,408 · Disposition to issuer (D): 4,595 (derivative) @ $10.50 · Disposition to issuer (D): 5,796 (derivative) @ $12.64 · Disposition to issuer (D): 5,656 (derivative) @ $13.25 | EDGAR |
| 2023-01-31 | 4 | WELTZIEN LOURDES — Executive VP, Life Science | Grant/award (A): 7,945 · Disposition to issuer (D): 86,045 · Disposition to issuer (D): 10,000 (derivative) @ $14.34 · Disposition to issuer (D): 2,500 (derivative) @ $19.70 · Disposition to issuer (D): 12,107 (derivative) @ $15.52 · Disposition to issuer (D): 11,669 (derivative) @ $15.12 | EDGAR |
| 2023-01-09 | 4 | Anderson James M. — Director | Option exercise (M): 8,500 @ $20.38 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | Smith Julie Diana — Sr VP, Controller, PAO | Tax withholding (F): 374 @ $31.71 | EDGAR |
| 2022-11-17 | 4 | Smith Julie Diana — Sr VP, Controller, PAO | Tax withholding (F): 1,845 @ $31.83 | EDGAR |
| 2022-11-17 | 4 | Serafini-Lamanna Tony — Executive VP-Diagnostics | Tax withholding (F): 3,666 @ $31.83 | EDGAR |
| 2022-11-17 | 4 | WELTZIEN LOURDES — EVP, Life Science | Tax withholding (F): 4,382 @ $31.83 | EDGAR |
| 2022-11-08 | 4 | Smith Julie Diana — Sr VP, Controller, PAO | Tax withholding (F): 397 @ $32.01 | EDGAR |
| 2022-11-08 | 4 | Serafini-Lamanna Tony — Executive VP-Diagnostics | Tax withholding (F): 788 @ $32.01 | EDGAR |
| 2022-11-08 | 4 | Kenny John P. — Chief Executive Officer, Director | Tax withholding (F): 4,271 @ $32.01 | EDGAR |
| 2022-11-08 | 4 | WELTZIEN LOURDES — EVP, Life Science | Tax withholding (F): 566 @ $32.01 | EDGAR |
| 2022-10-05 | 4 | Smith Julie Diana — Sr VP, Controller, PAO | Tax withholding (F): 360 @ $32.14 | EDGAR |
| 2022-10-05 | 4 | Serafini-Lamanna Tony — Executive VP-Diagnostics | Tax withholding (F): 357 @ $32.14 | EDGAR |
| 2022-10-05 | 4 | Kenny John P. — Chief Executive Officer, Director | Tax withholding (F): 40,269 @ $31.53 | EDGAR |
| 2022-06-28 | 4 | Kenny John P. — Chief Executive Officer, Director | Option exercise (M): 13,559 @ $10.10 · Sale (S): 13,559 @ $30.00 · Option exercise (M): 61,437 @ $10.10 · Sale (S): 61,437 @ $30.39 · Option exercise (M): 13,559 (derivative) @ $0 · Option exercise (M): 61,437 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Kenny John P. — Chief Executive Officer, Director | Option exercise (M): 44,651 @ $14.50 · Sale (S): 44,651 @ $29.72 · Option exercise (M): 5,349 @ $14.50 · Option exercise (M): 14,607 @ $10.10 · Sale (S): 19,956 @ $29.98 · Option exercise (M): 44,651 (derivative) @ $0 · +2 more | EDGAR |
| 2022-02-28 | 4 | Kitzmiller Andrew S. — EVP & CFO | Purchase (P): 4,028 @ $24.87 | EDGAR |
| 2022-02-22 | 4 | Kitzmiller Andrew S. — EVP & CFO | Grant/award (A): 7,500 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | WELTZIEN LOURDES — EVP, Life Science | Option exercise (M): 12,500 @ $14.65 · Option exercise (M): 7,500 @ $14.30 · Sale (S): 20,000 @ $25.60 · Option exercise (M): 12,500 (derivative) @ $0 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Rice John McCune Jr. — Director | Grant/award (A): 3,012 @ $0 · Grant/award (A): 5,656 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Williams Felicia — Director | Grant/award (A): 3,012 @ $0 · Grant/award (A): 5,656 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Sazdanoff Catherine — Director | Grant/award (A): 3,012 @ $0 · Grant/award (A): 5,656 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | McIlwraith John — Director | Grant/award (A): 3,012 @ $0 · Grant/award (A): 5,656 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Ellingwood Dwight E — Director | Grant/award (A): 3,012 @ $0 · Grant/award (A): 5,656 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Anderson James M. — Director | Grant/award (A): 3,012 @ $0 · Grant/award (A): 5,656 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Bihl Anthony P III — Director | Grant/award (A): 3,012 @ $0 · Grant/award (A): 5,656 (derivative) @ $0 | EDGAR |
| 2022-01-14 | 4 | PHILLIPS DAVID — Director | Option exercise (M): 7,500 @ $18.54 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2021-12-22 | 4 | Baldasare Bryan T — Exec VP & CFO | Tax withholding (F): 1,985 @ $17.92 | EDGAR |
| 2021-12-22 | 4 | WELTZIEN LOURDES — EVP, Life Science | Tax withholding (F): 320 @ $17.92 | EDGAR |
| 2021-12-16 | 4 | Serafini-Lamanna Tony — Executive VP-Diagnostics | Tax withholding (F): 2,232 @ $20.16 | EDGAR |
| 2021-12-16 | 4 | Baldasare Bryan T — Exec VP & CFO | Tax withholding (F): 3,807 @ $20.16 | EDGAR |
| 2021-12-16 | 4 | WELTZIEN LOURDES — EVP, Life Science | Tax withholding (F): 4,269 @ $20.16 | EDGAR |
| 2021-11-16 | 4 | Serafini-Lamanna Tony — Executive VP-Diagnostics | Other (J): 24,343 · Grant/award (A): 24,343 | EDGAR |
| 2021-11-16 | 4 | Baldasare Bryan T — Exec VP & CFO | Other (J): 32,557 · Grant/award (A): 32,557 | EDGAR |
| 2021-11-16 | 4 | Kenny John P. — Chief Executive Officer, Director | Other (J): 155,511 · Grant/award (A): 155,511 | EDGAR |
| 2021-11-16 | 4 | WELTZIEN LOURDES — EVP, Life Science | Other (J): 32,709 · Grant/award (A): 32,709 | EDGAR |
| 2021-11-08 | 4 | Baldasare Bryan T — Exec VP & CFO | Grant/award (A): 10,593 @ $0 · Grant/award (A): 11,669 (derivative) @ $0 | EDGAR |
| 2021-11-08 | 4 | Kenny John P. — Chief Executive Officer, Director | Grant/award (A): 56,472 @ $0 · Grant/award (A): 82,940 (derivative) @ $0 | EDGAR |
| 2021-11-08 | 4 | WELTZIEN LOURDES — EVP, Life Science | Grant/award (A): 10,593 @ $0 · Grant/award (A): 11,669 (derivative) @ $0 | EDGAR |
Recent 8-K events — VivoPower PLC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-02-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-22 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-10-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2022-09-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2022-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-07-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-07-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-07-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VIVO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs